AU777537B2 - Use of riluzole for the treatment of multiple sclerosis - Google Patents

Use of riluzole for the treatment of multiple sclerosis Download PDF

Info

Publication number
AU777537B2
AU777537B2 AU54219/00A AU5421900A AU777537B2 AU 777537 B2 AU777537 B2 AU 777537B2 AU 54219/00 A AU54219/00 A AU 54219/00A AU 5421900 A AU5421900 A AU 5421900A AU 777537 B2 AU777537 B2 AU 777537B2
Authority
AU
Australia
Prior art keywords
treatment
pharmaceutical composition
multiple sclerosis
benzothiazolamine
trifluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54219/00A
Other languages
English (en)
Other versions
AU5421900A (en
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Amsterdam
Original Assignee
Vrije Universiteit Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Amsterdam filed Critical Vrije Universiteit Amsterdam
Publication of AU5421900A publication Critical patent/AU5421900A/en
Application granted granted Critical
Publication of AU777537B2 publication Critical patent/AU777537B2/en
Assigned to VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS reassignment VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS Request to Amend Deed and Register Assignors: VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIKJK ONDERWIJS
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU54219/00A 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis Ceased AU777537B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
US60/174328 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005200244A Division AU2005200244A1 (en) 1999-06-04 2005-01-21 Use of Riluzole for the Treatment of Multiple Sclerosis

Publications (2)

Publication Number Publication Date
AU5421900A AU5421900A (en) 2000-12-28
AU777537B2 true AU777537B2 (en) 2004-10-21

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54219/00A Ceased AU777537B2 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Country Status (11)

Country Link
EP (2) EP1552831B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003522121A (cg-RX-API-DMAC7.html)
AT (2) ATE287713T1 (cg-RX-API-DMAC7.html)
AU (1) AU777537B2 (cg-RX-API-DMAC7.html)
CA (1) CA2375874A1 (cg-RX-API-DMAC7.html)
DE (1) DE60017733T2 (cg-RX-API-DMAC7.html)
ES (1) ES2235896T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ515685A (cg-RX-API-DMAC7.html)
PT (1) PT1187612E (cg-RX-API-DMAC7.html)
SI (1) SI1187612T1 (cg-RX-API-DMAC7.html)
WO (1) WO2000074676A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017683A1 (fr) * 1992-03-06 1993-09-16 Rhone-Poulenc Rorer S.A. Application de l'amino-2 trifluoromethoxy-6 benzothiazole (riluzole) pour obtenir un medicament destine au traitement des maladies du motoneurone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513698A (ja) * 1995-10-25 1999-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経保護物質およびパーフルオロケミカルの注射剤
US6133258A (en) * 1995-11-05 2000-10-17 Yamanouchi Pharmaceutical Co., Ltd. Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017683A1 (fr) * 1992-03-06 1993-09-16 Rhone-Poulenc Rorer S.A. Application de l'amino-2 trifluoromethoxy-6 benzothiazole (riluzole) pour obtenir un medicament destine au traitement des maladies du motoneurone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. STANKOFF NEUROLOGY, VOL.52,NO.6,12 APRIL 1999 *
G. MCCREADY JUNE 1998 (1998-06),MS PATHFINDER *

Also Published As

Publication number Publication date
JP2003522121A (ja) 2003-07-22
WO2000074676A1 (en) 2000-12-14
EP1187612A1 (en) 2002-03-20
EP1187612B1 (en) 2005-01-26
EP1552831B1 (en) 2009-01-07
NZ515685A (en) 2002-12-20
ATE419851T1 (de) 2009-01-15
SI1187612T1 (en) 2005-06-30
ES2235896T3 (es) 2005-07-16
PT1187612E (pt) 2005-05-31
CA2375874A1 (en) 2000-12-14
DE60017733D1 (de) 2005-03-03
ATE287713T1 (de) 2005-02-15
AU5421900A (en) 2000-12-28
EP1552831A1 (en) 2005-07-13
DE60017733T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
US20080214631A1 (en) Use of riluzole for the treatment of multiple sclerosis
US20110046119A1 (en) Therapeutic treatment
AU777537B2 (en) Use of riluzole for the treatment of multiple sclerosis
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
HK1076049B (en) Use of riluzole for treating multiple sclerosis
JP2004512376A (ja) 虚血性障害の処置用医薬品の製造のためのメラガトランの使用
US9248118B2 (en) Compositions and method for treatment of ischemic neuronal reperfusion injury
JPH09221425A (ja) チオールプロテアーゼ阻害剤
EP1581227B1 (en) A method for treating renal failure
WO2010042841A1 (en) Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system
JPWO2020234782A5 (cg-RX-API-DMAC7.html)
JPH0415766B2 (cg-RX-API-DMAC7.html)
JPH05310573A (ja) リウマチ治療薬
AU2008201290B2 (en) Therapeutic treatment
HK1090553B (en) A combination comprising candesartan and rosuvastatin for the treatment of atherosclerosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME BY DELETING BIOGEN, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired